Tag : Seladelpar

Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease that primarily affects women and is characterized by the progressive destruction of bile ducts. This condition can lead to liver injury, fibrosis, and ultimately cirrhosis. To address the unmet needs of patients inadequately responding to ursodeoxycholic acid (UDCA), seladelpar, a selective peroxisome proliferator-activated receptor delta (PPARδ) agonist, has emerged as a promising treatment option. The phase 3 RESPONSE trial was designed to evaluate the efficacy and safety of seladelpar in patients with PBC.